Evidence map›Paper›PMID 34355538›Full record

Trial reportESC heart failure2021

Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure.

Maria Belkin, Desiree Wussler, Danielle Menosi Gualandro, Samyut Shrestha, Ivo Strebel, Assen Goudev, Micha T Maeder, Joan Walter, Dayana Flores, Nikola Kozhuharov and 9 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 7 countries.

Maria BelkinCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0003-4643-8473
Desiree WusslerCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0002-1793-5297
Danielle Menosi GualandroCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0001-9041-6250
Samyut ShresthaCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0002-9189-3830
Ivo StrebelCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0001-9976-4112
Assen GoudevDepartment of Cardiology, Queen Ioanna University Hospital Sofia, Sofia, Bulgaria.ORCID 0000-0002-2014-1885
Micha T MaederDepartment of Cardiology, Cantonal Hospital St Gallen, St Gallen, Switzerland.ORCID 0000-0001-7036-5791
Joan WalterCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0001-6077-6941
Dayana FloresCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0002-4396-4008
Nikola KozhuharovCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0003-2086-3690
Pedro Lopez-AyalaCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0002-7787-0640
Isabelle DanierCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Mucio Tavares de Oliveira JuniorDepartment of Cardiology, University of Sao Paulo Medical School, Sao Paulo, Brazil.ORCID 0000-0001-9413-3792
Richard KobzaDepartment of Cardiology, Lucerne Cantonal Hospital, Lucerne, Switzerland.ORCID 0000-0003-3988-7262
Hans RickliDepartment of Cardiology, Cantonal Hospital St Gallen, St Gallen, Switzerland.ORCID 0000-0002-4070-6513
Tobias BreidthardtCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0003-2671-6456
Paul ErneDepartment of Cardiology, Lucerne Cantonal Hospital, Lucerne, Switzerland.ORCID 0000-0003-4535-2950
Thomas MünzelDepartment of Cardiology, University Medicine Mainz, Mainz, Germany.ORCID 0000-0001-5503-4150
Christian MuellerCardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University of Basel, Petersgraben 4, Basel, CH-4031, Switzerland.ORCID 0000-0002-1120-6405
University of Basel · CHUniversidade de São Paulo · BRUniversity of Lucerne · CHUniversity of St.Gallen · CHQueen Giovanna Hospital · BGUniversity of Applied Sciences Mainz · DEUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe aimed to assess the long-term effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life (HRQL) among patients with acute heart failure (AHF). METHODS AND

resultsHealth-related quality of life was prospectively assessed by the generic 3-levelled EQ-5D and the disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ) among adult AHF patients enrolled in an international, multicentre, randomised, open-label blinded-end-point trial of a strategy that emphasized early intensive and sustained vasodilation using maximally tolerated doses of established oral and transdermal vasodilators according to systolic blood pressure. Changes in EQ-5D and KCCQ from admission to 180 day follow-up were individually compared between the intensive vasodilatation and the usual care group. Among 666 patients eligible for 180 day follow-up, 284 (43%, median age 79 years, 35% women) and 198 (30%, median age 77 years, 35% women) had completed the EQ-5D and KCCQ at baseline and follow-up, respectively. There was a significant improvement in HRQL as quantified by both, EQ-5D and KCCQ, from hospitalization to 180 day follow-up, with no significant differences in the change of HRQL between both treatment strategies. For instance, 39 (26%) versus 33 (25%) patients had an improvement by at least one level in at least two categories in the EQ-5D. Median increase in KCCQ overall summary score (KCCQ-OSS) was 17.6 (IQR 2.0-42.6) in the intervention group versus 18.5 (IQR 3.9-39.3) in the usual care group (P < 0.001 vs. baseline, P = 0.945 between groups).

conclusionsAmong patients with AHF, long-term HRQL quantified by EQ-5D and KCCQ improved substantially, with overall no significant differences between a strategy of comprehensive vasodilation versus usual care.

Indexed as

Heart FailureQuality of LifeAdultAgedFemaleHospitalizationHumansMaleVasodilationVasodilator AgentsVasodilator AgentsAcute heart failureHealth-related quality of lifeSustained vasodilatation

Identifiers

PMID34355538
PMCPMC8497201
OpenAlexW3191921259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.